Gennex Lab. (531739)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Profit grew 18.01% despite modest 7.37% sales growth, showing operating leverage and margin improvement.
• Piotroski F-Score of 7/9 points to sound financial health with positive profitability and efficiency signals.
• ROCE of 13.01% indicates decent capital productivity for a small-cap pharma player.
• Latest quarter net profit of ₹6 Cr on ₹43 Cr sales gives a healthy margin of around 14%.
• PEG of 1.23 suggests valuation is not excessive if current earnings momentum continues.

Concerns

• ROE of 8.17% is weak; the business is not creating strong value for equity holders.
• Zero dividend yield means investors get no cash return while waiting for capital gains.
• Top-line growth of only 7.37% is sluggish; profit growth driven by margins may not be sustainable.
• Debt/equity and promoter holding are unavailable, leaving leverage and ownership alignment unclear.

AI Analysis

Whenever I look at a pharmaceutical company, I ask two questions: does it have a defensive moat, and can it compound capital at attractive rates? Gennex Lab fails my moat test from the numbers alone. It is a ₹315 Cr microcap with a P/E of 15.60 and a P/B of 1.84. A book value of ₹7.54 means the market expects some improvement. But with an ROE of 8.17%, the business is not generating exceptional returns on shareholder capital. ROCE at 13.01% is respectable, yet not the kind of franchise I can sleep on. The profit growth of 18.01% looks encouraging, but sales growth is only 7.37%. That tells me the extra profit is coming from margins, not from a powerful top line. The latest quarter's ₹43 Cr sales and ₹6 Cr profit imply a flattering margin, but I'd rather see volume growth and pricing power. The Piotroski F-Score of 7/9 suggests basic financial health, so it is not a burning house. The PEG ratio of 1.23 suggests the current price roughly matches growth. In other words, no bargain. There is no dividend, so I cannot be paid to wait. The 52-week range of ₹7.05 to ₹17.25 shows how quickly small pharma stocks swing. I would prefer a clean balance sheet, but debt/equity is not given; I cannot sign a check without understanding leverage. Also, promoter holding is not available, and for a micro-cap, owner alignment is critical. This looks like a slow grower with improving numbers, but not a wonderful business. If I owned it, I would watch whether return on equity moves toward double digits, whether sales growth accelerates, and whether margins hold. At the right price, it may be an okay investment, but at this price I'd want a margin of safety. Patience is my only edge.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer